EP2887924A1 - Pharmaceutical compositions of etoricoxib - Google Patents

Pharmaceutical compositions of etoricoxib

Info

Publication number
EP2887924A1
EP2887924A1 EP13770967.1A EP13770967A EP2887924A1 EP 2887924 A1 EP2887924 A1 EP 2887924A1 EP 13770967 A EP13770967 A EP 13770967A EP 2887924 A1 EP2887924 A1 EP 2887924A1
Authority
EP
European Patent Office
Prior art keywords
etoricoxib
pharmaceutical composition
pharmaceutically acceptable
enhancing agent
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP13770967.1A
Other languages
German (de)
French (fr)
Other versions
EP2887924B1 (en
Inventor
Roy Sunilendu BHUSHAN
Kulkarni Sushrut KRISHNAJI
Mehta Pavak RAJNIKANT
Kapoor RITESH
Maheshwari Rajeshkumar BHARAT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of EP2887924A1 publication Critical patent/EP2887924A1/en
Application granted granted Critical
Publication of EP2887924B1 publication Critical patent/EP2887924B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to pharmaceutical composition of etoricoxib or pharmaceutically acceptable salt thereof for oral administration. More particularly, it relates to a pharmaceutical composition of etoricoxib or pharmaceutically acceptable salt thereof, which comprises dry granulated particles of etoricoxib or pharmaceutically acceptable salt thereof and optionally, one or more pharmaceutically acceptable excipients.
  • Etoricoxib is a selective COX-2 inhibitor which has been shown to be as effective as nonselective non-steroidal anti-inflammatory drugs in the management of chronic pain in rheumatoid arthritis, osteoarthritis and other COX-2 mediated disorders.
  • Etoricoxib is 5-chloro-6'-methyl-3-[4- methylsulfonyI)phenyl]-2,3'-bipyridine having structural Formula I.
  • Etoricoxib is a potent and selective cyclooxygenase-2 (COX-2) inhibitor.
  • Etoricoxib belongs to a class of drugs known as COX-2 inhibitors that are used in the treatment of COX-2 mediated disorders.
  • the therapeutic application of etoricoxib as a COX-2 inhibitor is disclosed in WO 96/10012 and WO 96/16934. This compound is disclosed in US Patent No. 5,861,419, which is hereby incorporated by reference in its entirety.
  • PCT publication No. WO 2005/085199 discloses etoricoxib Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV and Form XVI.
  • PCT publication No. WO 2006/043025 discloses granular compositions comprising solidified melt granules of COX-2 selective inhibitor.
  • PCT publication No. WO 2006/052503 discloses a wurster granulation process, a process for granulating particles by subjecting the particles to a repeated circulating movement in which particles are subjected to a spray of droplets of granulation solution.
  • compositions of etoricoxib may be prepared by techniques known in the art i.e. wet granulation, dry granulation, direct compression or melt granulation.
  • wet granulation dry granulation
  • direct compression or melt granulation we have found that when the composition of etoricoxib is prepared by wet granulation using water, there exists a polymorphic conversion of etoricoxib in the composition, which may lead to decrease in solubility and/or stability of the final composition.
  • Figure 1 illustrates an XPRD pattern of crystalline etoricoxib active ingredient.
  • Figure 2 illustrates an XPRD pattern of placebo.
  • Figure 3 illustrates an XPRD pattern of tablet containing crystalline etoricoxib active ingredient.
  • a pharmaceutical composition comprising dry granulated particles of etoricoxib or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.
  • a pharmaceutical composition comprising etoricoxib or pharmaceutically acceptable salt thereof, at least one solubility enhancing agent, and one or more pharmaceutically acceptable excipients, wherein the amount of dissolution enhancing agent ranges from about 0.01 to about 10 % w/w of the composition.
  • a pharmaceutical composition comprising etoricoxib or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, wherein the particle size distribution of etoricoxib or pharmaceutically acceptable salt thereof is such that D90 is less than about 250 ⁇ , D 50 is less than about 100 ⁇ and D10 is less than about 50 ⁇ or any combination thereof.
  • a pharmaceutical composition comprising etoricoxib or pharmaceutically acceptable salt thereof, at least one solubility enhancing agent, and one or more pharmaceutically acceptable excipients, wherein the particle size distribution of etoricoxib or pharmaceutically acceptable salt thereof is such that D90 is less than about 250 ⁇ , D 50 is less than about 100 ⁇ and D t0 is less than about 50 ⁇ or any combination thereof.
  • Embodiments of the pharmaceutical composition may include one or more of the following features.
  • the pharmaceutical composition may include one or more pharmaceutically acceptable excipients selected from binders, fillers, lubricants, disintegrants, glidants, antioxidants, soIvents,ilavors, sweeteners and the like.
  • the stable composition of etoricoxib can be prepared by dry granulation process to avoid polymorphic conversion of etoricoxib in the composition.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising dry granulated particles of etoricoxib or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.
  • etoricoxib is used in broad sense to include not only the etoricoxib per se but also its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs and pharmaceutically acceptable prodrugs thereof, and also its various crystalline and amorphous forms.
  • etoricoxib is present in several alternate crystalline or amorphous , including forms I, II, III, IV, V, IX, X, XI, XII, XIII, XIV, XV, XVI or mixtures thereof. More preferably, the etoricoxib is etoricoxb form I.
  • dry granulation means the process of blending bulk etoricoxib with at least one excipient.
  • the blend is then compressed, or compacted to form a compressed material or "compact”.
  • This material is then broken apart to form granules by crushing, grinding or cutting into dry granulated particles.
  • the particles may be further processed. Crushing, grinding, or cutting processes involve an operation that reduces the size of the compressed material such as accomplished by milling or by other operations known to those skilled in the art.
  • a “compact” is a compressed material formed by processing etoricoxib and optional excipients by slugging or by roller compaction.
  • Grams or “dry granulated particles” are defined herein as particles containing etoricoxib and one or more pharmaceutically acceptable excipients, that are formed by dry granulation process.
  • a pharmaceutical composition comprising etoricoxib or pharmaceutically acceptable salt thereof, which comprises at least one solubility enhancer.
  • solubility enhancing agent used throughout the description to include surfactants; hydrocolloids such as cellulose derivatives (e.g. hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyl methyl cellulose); polymers such as N-vinyl- 2-pyrrolidone, polyvinyl pyrrolidone; copolymers such as copolymer of vinylpyrrolidone (VP) and vinylacetate (VA).
  • solubility enhancing agent used in the pharmaceutical composition of etoricoxib is sodium lauryl sulphate.
  • Suitable "surfactants" which can be used for preparing pharmaceutical composition of etoricoxib may include one or more of anionic, cationic, non-ionic or zwitterionic surfactants or mixtures thereof.
  • Suitable cationic surfactants may include one or more of quaternary ammonium compounds, such as benzalkonium chloride, cetyl trimethyl ammonium bromide and dodecyl dimethyl ammonium bromide, hexadecyl (cetyl) trimethylammonium bromide, dodecyl pyridinium chloride, lauryl dimethyl benzyl ammonium chloride, acyl carnitine hydrochlorides, alkyl pyridinium halides, dodecylamine hydrochloride and the like.
  • quaternary ammonium compounds such as benzalkonium chloride, cetyl trimethyl ammonium bromide and dodecyl dimethyl ammonium bromide, hexadecyl (cetyl) trimethylammonium bromide, dodecyl pyridinium chloride, lauryl dimethyl benzyl ammonium chloride, acyl carnitine hydrochlorides
  • Suitable anionic surfactants may include one or more of salts of aliphatic monoesters of sulfuric acid and soaps, such as potassium laurate; sodium dodecyl sulphate; alkyl polyoxyethylene sulfates; sodium alginates; sodium lauryl sulphate and sodium heptadecyl sulphate; sulfonated aromatic agents such as alkyl benzene sulfonic acids and salts thereof, such as tridecylbenzene sulphonic acid and the sodium and amino salts of dodecylbenzene sulphonic acid; alkyl naphthalene sulfonates, such as sodium butylnaphthalene sulphonate, sulphosuccinates such as sodium dioctyl sulphosuccinate and N-acyl-N-alkyl fatty acid taurates; sulfated polyoxyethylated alcohols; sulfated oils; dioc
  • Suitable non-ionic surfactants may include one or more of polyoxyethylene fatty alcohol ethers (Macrogol and Brij), polyoxyethylene sorbitan fatty acid esters (Polysorbates), polyoxyethylene fatty acid esters (Myrj), sorbitan esters (Span), glycerol monostearate, polyethylene glycols, polypropylene glycols, cetyl alcohol, cetostearyl alcohol, stearyl alcohol, aryl alkyl polyether alcohols, polyoxyethylene-polyoxypropylene copolymers (poloxomers), polaxamines, methylcellulose, hydroxycellulose, hydroxy propylcellulose, hydroxy propylmethylcellulose, noncrystalline cellulose, polyvinyl alcohol, polyvinylpyrrolidone, and the like.
  • polyoxyethylene fatty alcohol ethers Macrogol and Brij
  • Polysorbates polyoxyethylene sorbitan fatty acid esters
  • Myrj polyoxyethylene fatty acid esters
  • Span
  • Suitable zwitterionic surfactants may include one or more of alkyl betaines, alkyl amidopropyl betaines, alkyl sulphobetaines, alkyl glycinates, alkyl carboxyglycinates, alkyl amphopropionates, alkyl amidopropyl hydroxysultaines, acyl taurates and acyl glutamates wherein the alkyl and acyl groups have from 8 to 18 carbon atoms such as cocamidopropyl betaine, sodium cocoamphoacetate, cocamidopropyl hydroxysultaine, sodium cocamphopropionate,.and the like.
  • the nonionic surfactant is a polyoxyethylene and polyoxypropylene copolymer and preferably a block copolymer of propylene glycol and ethylene glycol.
  • Such polymers are sold under the tradename Poloxamer also sometimes referred to as Pluronic.
  • Poloxamer also sometimes referred to as Pluronic.
  • polyoxyethylene fatty acid esters is included those having short alkyl chains.
  • such a surfactant is selected from Solutol ® , HS 15, polyethylene-660-hydroxystearate or the like.
  • a pharmaceutical composition comprising etoricoxib or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, wherein the particle size distribution of etoricoxib or pharmaceutically acceptable salt thereof is such that D 90 is less than about 250 ⁇ , D 5 o is less than about 100 ⁇ and Di 0 is less than about 50 ⁇ or any combination thereof.
  • a pharmaceutical composition comprising etoricoxib or pharmaceutically acceptable salt thereof and at least one solubility enhancing agent, wherein the particle size distribution of etoricoxib or pharmaceutically acceptable salt thereof is such that D 90 is less than about 250 ⁇ , D 50 is less than about 100 ⁇ and D )0 is less than about 50 ⁇ or any combination thereof.
  • the composition may be seal coated composition.
  • the composition is seal coated and finally film coated.
  • the composition can be coated with ready color mix systems (such as opadry color mix systems).
  • compositions for use in the pharmaceutical composition comprise one or more diluents, bulking agents, binders, disintegrants, glidants, lubricants, sweeteners/taste masking agents, compression aids, colorants and flavors.
  • Suitable diluents or bulking agents which includes, but are not limited to, saccharides, including monosaccharides, disaccharides, polysaccharides and sugar alcohols such as arabinose, lactose, dextrose, sucrose, fructose, maltose, mannitol, erythritol, sorbitol, xylitol lactitol, and other bulking agents such as powdered cellulose, microcrystalline cellulose (e.g. MCC PH 101 and MCC PH 102), purified sugar and derivatives thereof.
  • the formulation may incorporate one or more of the above bulking agents, preferably, lactose & microcrystalline cellulose forms the bulking agent.
  • Suitable binders or binders which includes, but are not limited to, methyl cellulose, hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), starch, gelatin, gum Arabic, ethyl cellulose, polyvinyl alcohol, tragacanth, sodium alginate and equivalents thereof.
  • Suitable disintegrants which includes, but are not limited to,, croscarmellose sodium, crospovidone, sodium starch glycolate, corn starch, potato starch, maize starch and modified starches, calcium silicates, low substituted hydroxy- propylcellulose.
  • Suitable lubricants and glidants which may include, but are not limited to, stearic acid and its derivatives or esters like sodium stearate, magnesium stearate and calcium stearate and the corresponding esters such as sodium stearyl fumarate; talc and colloidal silicon dioxide respectively.
  • Suitable taste masking agents may include one or more of polymers, sweeteners and flavors.
  • Most preferred polymers include one or more of cellulose acetate, polymethacrylates, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxylethyl cellulose; and the like.
  • Most preferred sweeteners include but not limiting to one or more of aspartame, saccharin, sucralose, glycyrrhizin; and the like.
  • Suitable sweeteners that may be used, comprises saccharides such as sucrose, dextrose, glucose, maltose, dextrins, D-tagatose, trehalose, dried invert sugar, fructose, levulose, galactose, corn syrup solids, and the like, alone or in combination.
  • Other examples of sweeteners comprise sodium saccharin; aspartame; sugarless sweeteners including polyhydric alcohols such as sorbitol, mannitol, xylitol, glycerol, hydrogenated starch hydrolysates, maltitol, isomaltitol, erythritol, lactitol and the like, alone or in combination.
  • Suitable flavors comprise cinnamon, wintergreen, eucalyptus, spearmint, peppermint, menthol, anise as well as fruit flavors such as apple, pear, peach, strawberry, cherry, apricot, orange, watermelon, banana and the like; bean-derived flavors, such as coffee, cocoa and the like or mixtures thereof.
  • etoricoxib composition may be prepared by granulating a blend of etoricoxib or pharmaceutically acceptable salt thereof, a solubility enhancing agent and one or more pharmaceutical excipients. The resulting granules may be compressed to form tablets or filled in hard gelatin capsules.
  • the various components may be weighed, delumped.
  • the mixing may be carried out for a sufficient period of time to produce a homogeneous blend.
  • Lubricant may be added in one, or multiple steps, prior to and/or after initial blending of the etoricoxib or pharmaceutically acceptable salt thereof and other excipients. Afterwards, the final mixing may be carried out.
  • the blend may be stored for later use.
  • the components of the blend including the etoricoxib or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, may be combined by blending, mixing, stirring, shaking, tumbling, rolling or by any other methods of combining the formulation components to achieve a homogeneous blend. It is preferable that the etoricoxib and excipients are combined under low shear conditions in a suitable apparatus, such as a V-blender, tote blender, double cone blender or any other apparatus capable of functioning under preferred low shear conditions. Lubricant is typically added in the last step.
  • the invention should not be considered limited to these particular conditions for combining the components and it will be understood, based on this disclosure that the advantageous properties can be achieved through other conditions provided the components retain their basic properties and substantial homogeneity of the blended formulation components of the formulation is otherwise achieved without any significant segregation.
  • the components may be weighed and placed into a blending container. Blending may be performed for a period of time to produce a homogenous blend using suitable mixing equipment.
  • the blend may be passed through a mesh screen to delump the blend.
  • the screened blend may be returned to the blending container and blended for an additional period of time. Lubricant may then be added and the blend mixed for an additional period of time.
  • the blend, of the present invention may be then compressed, or compacted, to form a compact.
  • the blend Prior to compression, the blend may be subjected to a precompression step such as on a rotary tablet press. Compression of the blend to form granules may be accomplished by techniques known in the art including slugging where the blend may be introduced into dies comprising one or more punch faces that are installed on a press such as a tablet press and pressure may be applied to the blend by the movement of one or more punch faces in the die. Dry granulation may also be performed through the use of a roller compactor.
  • a roller compactor generally incorporates two or more rollers adjacent and parallel to each other with a fixed or adjustable gap between the rollers.
  • a hopper or other feeding device deposits blend between the moving rollers which act to compact the blend into a compacted material.
  • Roller compactors are typically equipped with dividers that cut or otherwise divide the compacted material emerging from the roller compactor into ribbons.
  • An example of a roller compactor is TF-Mini 15 Roller Compactor (Vector Corporation, Marion, IA, Freund).
  • the compact may be then broken apart to form granules, typically by suitable mechanical means, such as by crushing, grinding or cutting.
  • the dry granulated tablet may comprise an amount of glidant that is less than about 3% by weight, based on the tablet weight.
  • the direct compression tablet may comprise an amount of glidant that is less than about 1% by weight, based on the tablet weight. In an even further embodiment, the tablet may comprise an amount of glidant that is less than about 0.5% by weight, based on the weight of the glidant.
  • Suitable glidants include magnesium trisilicate, powdered cellulose, starch, talc, tribasic calcium phosphate, stearate salts and colloidal silicon dioxide. Most preferred glidants are talc, magnesium stearate and colloidal silicon dioxide.
  • the tablet may be coated.
  • the reasons for coating a tablet may include masking the taste of the drug, making tablets easier to swallow, protection against chipping during packaging, a barrier for moisture or light to improve product stability, and enhancing product appearance or recognition.
  • the invention further provides a method of treating pain and inflammatory signs comprising administering to said subject a pharmaceutical composition of etoricoxib or pharmaceutically acceptable salt thereof as substantially disclosed hereinbefore.
  • Etoricoxib, sodium lauryl sulphate, low substituted hydroxyl propyl cellulose, microcrystalline cellulose, calcium hydrogen phosphate and croscarmellose sodium were mixed together and lubricated with magnesium stearate.
  • the blend was then dry granulated using roll compactor to achieve desired granules. Blend the granules with remaining quantity of croscarmellose sodium and colloidal silicon dioxide followed by lubrication with magnesium stearate and compressed using suitable punch tooling.
  • Etoricoxib, low substituted hydroxyl propyl cellulose, microcrystalline cellulose, calcium hydrogen phosphate, croscarmellose sodium and colloidal silicon dioxide were mixed together and lubricated with magnesium stearate.
  • the blend was then dry granulated using roll compactor to achieve desired granules. Blend the granules with remaining quantity of croscarmellose sodium and colloidal silicon dioxide followed by lubrication with magnesium stearate and compressed using suitable punch tooling.
  • Table 3 provides dissolution data of etoricoxib tablet prepared as per Example 1 , 2 and reference formulation (Arocixa ® Tablet).
  • USP Type II (Paddle) apparatus 50rpm was used wherein 900ml of pH 6.8 Phosphate buffer was used as medium.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention discloses a pharmaceutical composition comprising etoricoxib or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients and the process of preparing the composition.

Description

PHARMACEUTICAL COMPOSITIONS OF ETORICOXIB
FIELD OF THE INVENTION
The present invention relates to pharmaceutical composition of etoricoxib or pharmaceutically acceptable salt thereof for oral administration. More particularly, it relates to a pharmaceutical composition of etoricoxib or pharmaceutically acceptable salt thereof, which comprises dry granulated particles of etoricoxib or pharmaceutically acceptable salt thereof and optionally, one or more pharmaceutically acceptable excipients.
BACKGROUND OF THE INVENTION
Etoricoxib is a selective COX-2 inhibitor which has been shown to be as effective as nonselective non-steroidal anti-inflammatory drugs in the management of chronic pain in rheumatoid arthritis, osteoarthritis and other COX-2 mediated disorders. Etoricoxib is 5-chloro-6'-methyl-3-[4- methylsulfonyI)phenyl]-2,3'-bipyridine having structural Formula I.
Formula I
Etoricoxib is a potent and selective cyclooxygenase-2 (COX-2) inhibitor. Etoricoxib belongs to a class of drugs known as COX-2 inhibitors that are used in the treatment of COX-2 mediated disorders. The therapeutic application of etoricoxib as a COX-2 inhibitor is disclosed in WO 96/10012 and WO 96/16934. This compound is disclosed in US Patent No. 5,861,419, which is hereby incorporated by reference in its entirety.
A process for preparation of this compound is disclosed in US Patent No. 6,040,319, which is hereby incorporated by reference in its entirety. PCT publication No. WO 01/992230 discloses Form V of etoricoxib. It further discloses five polymorphic forms, one amorphous form and two hydrated forms, which also hereby incorporated by reference in its entirety. Thus it describes eight new forms of etoricoxib.
PCT publication No. WO 2005/085199 discloses etoricoxib Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV and Form XVI.
PCT publication No. WO 2006/043025 discloses granular compositions comprising solidified melt granules of COX-2 selective inhibitor.
PCT publication No. WO 2006/052503 discloses a wurster granulation process, a process for granulating particles by subjecting the particles to a repeated circulating movement in which particles are subjected to a spray of droplets of granulation solution.
Compositions of etoricoxib may be prepared by techniques known in the art i.e. wet granulation, dry granulation, direct compression or melt granulation. We have found that when the composition of etoricoxib is prepared by wet granulation using water, there exists a polymorphic conversion of etoricoxib in the composition, which may lead to decrease in solubility and/or stability of the final composition. We have surprisingly found that there is no polymorphic conversion of etoricoxib in the composition while the composition is prepared by dry granulation process and thus the composition remains stable and the solubility of etoricoxib is not hampered.
BRIEF DESCRIPTION OF DRAWINGS
Figure 1 illustrates an XPRD pattern of crystalline etoricoxib active ingredient.
Figure 2 illustrates an XPRD pattern of placebo.
Figure 3 illustrates an XPRD pattern of tablet containing crystalline etoricoxib active ingredient.
SUMMARY OF THE INVENTION
In one general aspect, there is provided a pharmaceutical composition comprising dry granulated particles of etoricoxib or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.
In another general aspect, there is provided a pharmaceutical composition comprising etoricoxib or pharmaceutically acceptable salt thereof, at least one solubility enhancing agent, and one or more pharmaceutically acceptable excipients, wherein the amount of dissolution enhancing agent ranges from about 0.01 to about 10 % w/w of the composition.
In another general aspect, there is provided a pharmaceutical composition comprising etoricoxib or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, wherein the particle size distribution of etoricoxib or pharmaceutically acceptable salt thereof is such that D90 is less than about 250 μπι, D50 is less than about 100 μπι and D10 is less than about 50 μπι or any combination thereof.
In another general aspect, there is provided a pharmaceutical composition comprising etoricoxib or pharmaceutically acceptable salt thereof, at least one solubility enhancing agent, and one or more pharmaceutically acceptable excipients, wherein the particle size distribution of etoricoxib or pharmaceutically acceptable salt thereof is such that D90 is less than about 250 μιη, D50 is less than about 100 μπι and Dt0 is less than about 50 μπι or any combination thereof.
Embodiments of the pharmaceutical composition may include one or more of the following features. For example, the pharmaceutical composition may include one or more pharmaceutically acceptable excipients selected from binders, fillers, lubricants, disintegrants, glidants, antioxidants, soIvents,ilavors, sweeteners and the like.
The details of one or more embodiments of the invention are set forth in the description below. Other features, objects and advantages of the invention will be apparent from the description.
DETAILED DESCRIPTION OF THE INVENTION
The inventors of the present invention have surprisingly found that the stable composition of etoricoxib can be prepared by dry granulation process to avoid polymorphic conversion of etoricoxib in the composition.
The present invention provides a pharmaceutical composition comprising dry granulated particles of etoricoxib or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.
As used herein, the term "etoricoxib" is used in broad sense to include not only the etoricoxib per se but also its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs and pharmaceutically acceptable prodrugs thereof, and also its various crystalline and amorphous forms. Preferably, etoricoxib is present in several alternate crystalline or amorphous , including forms I, II, III, IV, V, IX, X, XI, XII, XIII, XIV, XV, XVI or mixtures thereof. More preferably, the etoricoxib is etoricoxb form I.
The term "dry granulation" means the process of blending bulk etoricoxib with at least one excipient. The blend is then compressed, or compacted to form a compressed material or "compact". This material is then broken apart to form granules by crushing, grinding or cutting into dry granulated particles. Optionally, the particles may be further processed. Crushing, grinding, or cutting processes involve an operation that reduces the size of the compressed material such as accomplished by milling or by other operations known to those skilled in the art.
A "compact" is a compressed material formed by processing etoricoxib and optional excipients by slugging or by roller compaction.
"Granules" or "dry granulated particles" are defined herein as particles containing etoricoxib and one or more pharmaceutically acceptable excipients, that are formed by dry granulation process.
In one of the embodiments of the present invention, there is provided a pharmaceutical composition comprising etoricoxib or pharmaceutically acceptable salt thereof, which comprises at least one solubility enhancer. The term "solubility enhancing agent" used throughout the description to include surfactants; hydrocolloids such as cellulose derivatives (e.g. hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyl methyl cellulose); polymers such as N-vinyl- 2-pyrrolidone, polyvinyl pyrrolidone; copolymers such as copolymer of vinylpyrrolidone (VP) and vinylacetate (VA). Preferably, solubility enhancing agent used in the pharmaceutical composition of etoricoxib is sodium lauryl sulphate.
Suitable "surfactants" which can be used for preparing pharmaceutical composition of etoricoxib may include one or more of anionic, cationic, non-ionic or zwitterionic surfactants or mixtures thereof.
Suitable cationic surfactants may include one or more of quaternary ammonium compounds, such as benzalkonium chloride, cetyl trimethyl ammonium bromide and dodecyl dimethyl ammonium bromide, hexadecyl (cetyl) trimethylammonium bromide, dodecyl pyridinium chloride, lauryl dimethyl benzyl ammonium chloride, acyl carnitine hydrochlorides, alkyl pyridinium halides, dodecylamine hydrochloride and the like.
Suitable anionic surfactants may include one or more of salts of aliphatic monoesters of sulfuric acid and soaps, such as potassium laurate; sodium dodecyl sulphate; alkyl polyoxyethylene sulfates; sodium alginates; sodium lauryl sulphate and sodium heptadecyl sulphate; sulfonated aromatic agents such as alkyl benzene sulfonic acids and salts thereof, such as tridecylbenzene sulphonic acid and the sodium and amino salts of dodecylbenzene sulphonic acid; alkyl naphthalene sulfonates, such as sodium butylnaphthalene sulphonate, sulphosuccinates such as sodium dioctyl sulphosuccinate and N-acyl-N-alkyl fatty acid taurates; sulfated polyoxyethylated alcohols; sulfated oils; dioctyl sodium sulfosuccinate, phosphatidyl choline, phosphatidyl glycerol, phosphatidyl inosine, phosphatidylserine, phosphatidic acid and their salts, glyceryl esters, sodium carboxymethylcellulose, cholic acid and other bile acids (e.g., cholic acid, deoxycholic acid, glycocholic acid, taurocholic acid, glycodeoxycholic acid) or salts thereof, and the like. The preferred anionic surfactant for use in etoricoxib composition is sodium lauryl sulphate.
Suitable non-ionic surfactants may include one or more of polyoxyethylene fatty alcohol ethers (Macrogol and Brij), polyoxyethylene sorbitan fatty acid esters (Polysorbates), polyoxyethylene fatty acid esters (Myrj), sorbitan esters (Span), glycerol monostearate, polyethylene glycols, polypropylene glycols, cetyl alcohol, cetostearyl alcohol, stearyl alcohol, aryl alkyl polyether alcohols, polyoxyethylene-polyoxypropylene copolymers (poloxomers), polaxamines, methylcellulose, hydroxycellulose, hydroxy propylcellulose, hydroxy propylmethylcellulose, noncrystalline cellulose, polyvinyl alcohol, polyvinylpyrrolidone, and the like.
Suitable zwitterionic surfactants may include one or more of alkyl betaines, alkyl amidopropyl betaines, alkyl sulphobetaines, alkyl glycinates, alkyl carboxyglycinates, alkyl amphopropionates, alkyl amidopropyl hydroxysultaines, acyl taurates and acyl glutamates wherein the alkyl and acyl groups have from 8 to 18 carbon atoms such as cocamidopropyl betaine, sodium cocoamphoacetate, cocamidopropyl hydroxysultaine, sodium cocamphopropionate,.and the like.
In a preferred embodiment of the invention, the nonionic surfactant is a polyoxyethylene and polyoxypropylene copolymer and preferably a block copolymer of propylene glycol and ethylene glycol. Such polymers are sold under the tradename Poloxamer also sometimes referred to as Pluronic. Among polyoxyethylene fatty acid esters is included those having short alkyl chains. For example, such a surfactant is selected from Solutol®, HS 15, polyethylene-660-hydroxystearate or the like.
In accordance with the present invention, there is provided a pharmaceutical composition comprising etoricoxib or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, wherein the particle size distribution of etoricoxib or pharmaceutically acceptable salt thereof is such that D90 is less than about 250 μηι, D5o is less than about 100 μπι and Di0 is less than about 50 μπι or any combination thereof.
In another embodiment of the invention, there is provided a pharmaceutical composition comprising etoricoxib or pharmaceutically acceptable salt thereof and at least one solubility enhancing agent, wherein the particle size distribution of etoricoxib or pharmaceutically acceptable salt thereof is such that D90 is less than about 250 μηι, D50 is less than about 100 μηι and D)0 is less than about 50 μηι or any combination thereof.
The composition may be seal coated composition. Preferably, the composition is seal coated and finally film coated. The composition can be coated with ready color mix systems (such as opadry color mix systems).
Pharmaceutically acceptable excipients for use in the pharmaceutical composition comprise one or more diluents, bulking agents, binders, disintegrants, glidants, lubricants, sweeteners/taste masking agents, compression aids, colorants and flavors.
Suitable diluents or bulking agents which includes, but are not limited to, saccharides, including monosaccharides, disaccharides, polysaccharides and sugar alcohols such as arabinose, lactose, dextrose, sucrose, fructose, maltose, mannitol, erythritol, sorbitol, xylitol lactitol, and other bulking agents such as powdered cellulose, microcrystalline cellulose (e.g. MCC PH 101 and MCC PH 102), purified sugar and derivatives thereof. The formulation may incorporate one or more of the above bulking agents, preferably, lactose & microcrystalline cellulose forms the bulking agent.
Suitable binders or binders, which includes, but are not limited to, methyl cellulose, hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), starch, gelatin, gum Arabic, ethyl cellulose, polyvinyl alcohol, tragacanth, sodium alginate and equivalents thereof.
Suitable disintegrants which includes, but are not limited to,, croscarmellose sodium, crospovidone, sodium starch glycolate, corn starch, potato starch, maize starch and modified starches, calcium silicates, low substituted hydroxy- propylcellulose.
Suitable lubricants and glidants which may include, but are not limited to, stearic acid and its derivatives or esters like sodium stearate, magnesium stearate and calcium stearate and the corresponding esters such as sodium stearyl fumarate; talc and colloidal silicon dioxide respectively.
Suitable taste masking agents may include one or more of polymers, sweeteners and flavors. Most preferred polymers include one or more of cellulose acetate, polymethacrylates, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxylethyl cellulose; and the like. Most preferred sweeteners include but not limiting to one or more of aspartame, saccharin, sucralose, glycyrrhizin; and the like.
Suitable sweeteners that may be used, comprises saccharides such as sucrose, dextrose, glucose, maltose, dextrins, D-tagatose, trehalose, dried invert sugar, fructose, levulose, galactose, corn syrup solids, and the like, alone or in combination. Other examples of sweeteners comprise sodium saccharin; aspartame; sugarless sweeteners including polyhydric alcohols such as sorbitol, mannitol, xylitol, glycerol, hydrogenated starch hydrolysates, maltitol, isomaltitol, erythritol, lactitol and the like, alone or in combination.
Suitable flavors that may be used, comprise cinnamon, wintergreen, eucalyptus, spearmint, peppermint, menthol, anise as well as fruit flavors such as apple, pear, peach, strawberry, cherry, apricot, orange, watermelon, banana and the like; bean-derived flavors, such as coffee, cocoa and the like or mixtures thereof.
In one embodiment, etoricoxib composition may be prepared by granulating a blend of etoricoxib or pharmaceutically acceptable salt thereof, a solubility enhancing agent and one or more pharmaceutical excipients. The resulting granules may be compressed to form tablets or filled in hard gelatin capsules.
To prepare the blend, the various components may be weighed, delumped. The mixing may be carried out for a sufficient period of time to produce a homogeneous blend. Lubricant may be added in one, or multiple steps, prior to and/or after initial blending of the etoricoxib or pharmaceutically acceptable salt thereof and other excipients. Afterwards, the final mixing may be carried out. The blend may be stored for later use.
The components of the blend, including the etoricoxib or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, may be combined by blending, mixing, stirring, shaking, tumbling, rolling or by any other methods of combining the formulation components to achieve a homogeneous blend. It is preferable that the etoricoxib and excipients are combined under low shear conditions in a suitable apparatus, such as a V-blender, tote blender, double cone blender or any other apparatus capable of functioning under preferred low shear conditions. Lubricant is typically added in the last step.
The invention should not be considered limited to these particular conditions for combining the components and it will be understood, based on this disclosure that the advantageous properties can be achieved through other conditions provided the components retain their basic properties and substantial homogeneity of the blended formulation components of the formulation is otherwise achieved without any significant segregation.
In another embodiment for preparing the blend, the components may be weighed and placed into a blending container. Blending may be performed for a period of time to produce a homogenous blend using suitable mixing equipment. Optionally, the blend may be passed through a mesh screen to delump the blend. The screened blend may be returned to the blending container and blended for an additional period of time. Lubricant may then be added and the blend mixed for an additional period of time.
The blend, of the present invention, may be then compressed, or compacted, to form a compact. Prior to compression, the blend may be subjected to a precompression step such as on a rotary tablet press. Compression of the blend to form granules may be accomplished by techniques known in the art including slugging where the blend may be introduced into dies comprising one or more punch faces that are installed on a press such as a tablet press and pressure may be applied to the blend by the movement of one or more punch faces in the die. Dry granulation may also be performed through the use of a roller compactor. A roller compactor generally incorporates two or more rollers adjacent and parallel to each other with a fixed or adjustable gap between the rollers. A hopper or other feeding device deposits blend between the moving rollers which act to compact the blend into a compacted material. Roller compactors are typically equipped with dividers that cut or otherwise divide the compacted material emerging from the roller compactor into ribbons. An example of a roller compactor is TF-Mini 15 Roller Compactor (Vector Corporation, Marion, IA, Freund).
The compact may be then broken apart to form granules, typically by suitable mechanical means, such as by crushing, grinding or cutting.
Though generally not required with dry granulated tablets, in an alternate embodiment the dry granulated tablet may comprise an amount of glidant that is less than about 3% by weight, based on the tablet weight.
In a further embodiment, the direct compression tablet may comprise an amount of glidant that is less than about 1% by weight, based on the tablet weight. In an even further embodiment, the tablet may comprise an amount of glidant that is less than about 0.5% by weight, based on the weight of the glidant.
Suitable glidants include magnesium trisilicate, powdered cellulose, starch, talc, tribasic calcium phosphate, stearate salts and colloidal silicon dioxide. Most preferred glidants are talc, magnesium stearate and colloidal silicon dioxide.
If desired, the tablet may be coated. The reasons for coating a tablet may include masking the taste of the drug, making tablets easier to swallow, protection against chipping during packaging, a barrier for moisture or light to improve product stability, and enhancing product appearance or recognition. The invention further provides a method of treating pain and inflammatory signs comprising administering to said subject a pharmaceutical composition of etoricoxib or pharmaceutically acceptable salt thereof as substantially disclosed hereinbefore.
The invention is further illustrated by the following examples which are provided to be exemplary of the invention and do not limit the scope of the invention. While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
Example 1:
Table 1
Process: Etoricoxib, sodium lauryl sulphate, low substituted hydroxyl propyl cellulose, microcrystalline cellulose, calcium hydrogen phosphate and croscarmellose sodium were mixed together and lubricated with magnesium stearate. The blend was then dry granulated using roll compactor to achieve desired granules. Blend the granules with remaining quantity of croscarmellose sodium and colloidal silicon dioxide followed by lubrication with magnesium stearate and compressed using suitable punch tooling.
Example 2:
Table 2
Process: Etoricoxib, low substituted hydroxyl propyl cellulose, microcrystalline cellulose, calcium hydrogen phosphate, croscarmellose sodium and colloidal silicon dioxide were mixed together and lubricated with magnesium stearate. The blend was then dry granulated using roll compactor to achieve desired granules. Blend the granules with remaining quantity of croscarmellose sodium and colloidal silicon dioxide followed by lubrication with magnesium stearate and compressed using suitable punch tooling.
Dissolution study of Examples 1&2:
Table 3 provides dissolution data of etoricoxib tablet prepared as per Example 1 , 2 and reference formulation (Arocixa® Tablet). For determination of drug release rate, USP Type II (Paddle) apparatus (50rpm) was used wherein 900ml of pH 6.8 Phosphate buffer was used as medium.
Table 3
While the invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the invention.

Claims

We Claim:
1. A pharmaceutical composition comprising etoricoxib or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients,, wherein the composition is prepared by dry granulation and said etoricoxib retains its original polymorphic form.
2. A pharmaceutical composition comprising etoricoxib or pharmaceutically acceptable salts thereof having D90 particle size of less than about 250 μιη.
3. A pharmaceutical composition of claim 1 , wherein etoricoxib is etoricoxib crystalline form I.
4. A pharmaceutical composition of claim 1 further comprises atleast one solubility enhancing agent.
5. A pharmaceutical composition of any preceding claim, wherein the amount of solubility enhancing agent ranges from about 0.01 % to about 10 % of the composition.
6. A pharmaceutical composition of any preceding claim, wherein the solubility enhancing agent is surfactant, hydrocolloids, . N-vinyl-2-pyrrolidone, polyvinyl pyrrolidone, copolymer of vinylpyrrolidone (VP) and vinylacetate (VA) or combination thereof.
7. A pharmaceutical composition of any preceding claim, wherein the solubility enhancing agent is sodium lauryl sulphate'.
8. A process for preparing pharmaceutical composition comprising:
i) mixing etoricoxib or pharmaceutically acceptable salt thereof, optionally a solubility enhancing agent and one or more pharmaceutical excipients.
ii) dry granulating the above mixture to achieve desired granules.
iii) lubricating the granules of step (ii) with lubricant and converting the resulting mixture into a solid dosage form.
9. A pharmaceutical composition of claim 8, wherein the solid dosage form is tablet.
10. A pharmaceutical composition of claim 8, wherein the solid dosage form is capsule.
EP13770967.1A 2012-08-27 2013-08-27 Pharmaceutical compositions of etoricoxib Active EP2887924B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2477MU2012 2012-08-27
PCT/IB2013/001850 WO2014033526A1 (en) 2012-08-27 2013-08-27 Pharmaceutical compositions of etoricoxib

Publications (2)

Publication Number Publication Date
EP2887924A1 true EP2887924A1 (en) 2015-07-01
EP2887924B1 EP2887924B1 (en) 2017-03-29

Family

ID=49274832

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13770967.1A Active EP2887924B1 (en) 2012-08-27 2013-08-27 Pharmaceutical compositions of etoricoxib

Country Status (5)

Country Link
EP (1) EP2887924B1 (en)
ES (1) ES2630051T3 (en)
HU (1) HUE033525T2 (en)
PL (1) PL2887924T3 (en)
WO (1) WO2014033526A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016015776A1 (en) * 2014-07-31 2016-02-04 Krka, D.D., Novo Mesto Pharmaceutical composition of etoricoxib
CN105250231B (en) * 2015-11-02 2020-05-12 北京泰德制药股份有限公司 Pharmaceutical composition containing etoricoxib and preparation method thereof
MX2016006464A (en) * 2016-05-18 2017-11-17 Laboratorios Liomont S A De C V Pharmaceutical composition of a combination of tramadol-etoricoxib hydrochloride for the treatment of pain.
MX2017009660A (en) 2017-07-26 2017-11-23 Laboratorios Liomont S A De C V Pharmaceutical composition with a range of ratio between tramadol chlorhydrate and etoricoxib for its administration for the treatment of pain.
CN107961222A (en) * 2017-12-08 2018-04-27 佛山市弘泰药物研发有限公司 A kind of Etoricoxib dispersible tablet and preparation method thereof
CN107998088A (en) * 2017-12-08 2018-05-08 佛山市弘泰药物研发有限公司 A kind of Etoricoxib stomach dissolution type pellet tablet and preparation method thereof
CN107898787B (en) * 2017-12-15 2018-11-30 扬子江药业集团上海海尼药业有限公司 A kind of pharmaceutical composition and its preparation and preparation method
WO2019130049A1 (en) 2017-12-29 2019-07-04 Grünenthal GmbH Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5739166A (en) 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
RS49945B (en) 1998-04-24 2008-09-29 Merck & Co.Inc., PROCEDURE FOR SYNTHESIZING COX-2 INHIBITORS
PH12001001175B1 (en) 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
WO2005085199A1 (en) 2004-01-14 2005-09-15 Cadila Healthcare Limited Novel polymorphs of etoricoxib
GB0423103D0 (en) 2004-10-19 2004-11-17 Boots Healthcare Int Ltd Therapeutic agents
US20080095850A1 (en) 2004-11-04 2008-04-24 Ho Jennifer S Process for Granulating Particles
PL387415A1 (en) * 2009-03-06 2010-09-13 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Pharmaceutical composition containing celecoxib and method of its manufacturing
EA023286B1 (en) * 2011-05-27 2016-05-31 ФАРМА ДжРС, Д.О.О. Process for the preparation of polymorphic form i of etoricoxib

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2014033526A1 *

Also Published As

Publication number Publication date
WO2014033526A9 (en) 2014-11-13
ES2630051T3 (en) 2017-08-17
EP2887924B1 (en) 2017-03-29
PL2887924T3 (en) 2017-09-29
HUE033525T2 (en) 2017-12-28
WO2014033526A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
EP2887924B1 (en) Pharmaceutical compositions of etoricoxib
EP2736499B1 (en) Sustained release tablet comprising pregabalin through two-phase release-controlling system
TWI872459B (en) Immediate-release tablets containing a drug and processes for forming the tablets
JPWO2009041651A1 (en) Fast disintegrating solid preparation
CN101287463A (en) Comprising 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)-ureido)-3-fluorophenoxy)-pyridine-2-carboxylic acid for the treatment of hyperproliferative diseases new pharmaceutical composition
WO2012164578A1 (en) Compositions and methods for preparing immediate release formulations of nilotinib
WO2017103876A1 (en) Solid oral dosage forms of eslicarbazepine
WO2019152798A1 (en) Pharmaceutical formulations
CA2599649C (en) Drug formulations having controlled bioavailability
EP3250188B1 (en) Pharmaceutical composition comprising aprepitant and method for the preparation thereof
US20100003319A1 (en) Raloxifene immediate release tablets
WO2014104989A1 (en) Pharmaceutical compositions comprising aripiprazole
JP7250305B2 (en) Pharmaceutical composition containing memantine or a pharmaceutically acceptable salt thereof and method for producing the same
WO2014030172A2 (en) Pharmaceutical formulations of rufinamide
EP1725217B1 (en) Processes for the preparation of solid dosage forms of amorphous valganciclovir hydrochloride
EP2976067B1 (en) Pharmaceutical composition comprising a fluoroquinolone antibacterial agent and method for the preparation thereof
HK40061820A (en) Immediate-release tablets containing a drug and processes for forming the tablets
HK40099995A (en) Immediate-release tablets containing a drug and processes for forming the tablets
HK40099995B (en) Immediate-release tablets containing a drug and processes for forming the tablets
HK40069271A (en) Immediate-release tablets containing a drug and processes for forming the tablets
WO2022029798A1 (en) Pharmaceutical compositions comprising ribociclib
EP2397121B1 (en) Pharmaceutical preparation containing Entacapone, Levodopa and Carbidopa
WO2000078290A2 (en) Pharmaceutical composition comprising a salt of paroxetine
EP2441438A1 (en) Sachet formulations of eslicarbazepine
WO2009105049A1 (en) Oral tablet compositions containing nateglinide and surfactan ph adjusting agent

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150226

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

TPAC Observations by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

17Q First examination report despatched

Effective date: 20160401

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20161024

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

INTG Intention to grant announced

Effective date: 20170125

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 879095

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170415

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013019213

Country of ref document: DE

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170629

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170329

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 879095

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170329

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2630051

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20170817

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170629

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20170928

Year of fee payment: 5

Ref country code: IT

Payment date: 20170830

Year of fee payment: 5

Ref country code: FR

Payment date: 20170822

Year of fee payment: 5

Ref country code: DE

Payment date: 20170822

Year of fee payment: 5

Ref country code: GR

Payment date: 20170811

Year of fee payment: 5

Ref country code: GB

Payment date: 20170822

Year of fee payment: 5

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20170401740

Country of ref document: GR

Effective date: 20171122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170731

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170729

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20170830

Year of fee payment: 5

Ref country code: SE

Payment date: 20170821

Year of fee payment: 5

Ref country code: PL

Payment date: 20170721

Year of fee payment: 5

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E033525

Country of ref document: HU

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013019213

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20180103

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170831

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170831

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20170831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170827

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170827

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170827

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602013019213

Country of ref document: DE

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20180827

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180828

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190307

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180827

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180831

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20190918

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180827

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180828

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180827

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329